INDACO® is a drug based on Nafazoline nitrate + Zinc sulphate
THERAPEUTIC GROUP: Ophthalmologicals - Decongestants and antiallergics
Indications INDIGO ® Naphazoline and Zinc sulphate
INDACO® is a medicinal specialty indicated in the treatment of irritative phenomena of the eye characterized by tearing, burning and itching.
Mechanism of action INDACO ® Naphazoline and Zinc sulphate
INDACO® is a drug consisting of two active ingredients with different and complementary biological activities.
More precisely, naphazoline is an imidazole derivative with a high decongestant power supported by the "sympathomimetic activity active against the alpha 1 and alpha 2 adrenergic receptors, expressed on vascular smooth muscle, and important in reducing the classic vascular congestion evidently associated with the" edema of the ocular mucosa; while zinc sulphate in addition to a modest astringent power is endowed with an antiseptic activity important in reducing the risk of infectious overlapping, often the cause of comorbidities.
All this is carried out locally without systemic complications, resulting therefore effective and safe from a clinical point of view.
Studies carried out and clinical efficacy
THE USE OF NAPHAZOLINE IN MYASTENIA GRAVIS
Muscle Nerve. 2011 Jul; 44: 41-4. doi: 10.1002 / mus. 22002. Epub 2011 Apr 12.
Topical naphazoline in the treatment of myasthenic blepharoptosis.
Nagane Y, Utsugisawa K, Suzuki S, Masuda M, Shimizu Y, Utsumi H, Uchiyama S, Suzuki N.
Work that demonstrates how the use of naphazoline-based eye drops can guarantee an effective improvement of symptoms related to myasthenia gravis such as blephatroptosis, that is the descent of the eyelid.
NEUROENDOCRINE EFFECTS OF NAPHAZOLINE
Pharmacology. 2002 Jul; 65: 155-61.
Naphazoline-induced neuroendocrine changes: increases in ANP and cGMP levels, but suppression of NE, 3H-NE, and cAMP levels in rabbit eyes.
Ogidigben MJ, Chu TC, Potter DE.
Interesting experimental molecular study that tests the ability of naphazoline to alter the neuroendocrine framework by promoting the expression of genes and transcription factors involved in neuroendocrine homeostasis.
ANALYTICAL CHEMISTRY OF NAFAZOLINE IN EYE DROPS
Chem Pharm Bull (Tokyo). 2006 Jan; 54: 119-22.
A rapid derivative spectrophotometric method for simultaneous determination ofnaphazoline and antazoline in eye drops.
Souri E, Amanlou M, Farsam H, Afshari A.
Technical study that evaluates the effectiveness of various chemical analytical methods in evaluating the concentrations of active ingredients such as naphazoline in eye drops, allowing a more accurate examination of the potential physico-chemical interactions associated with perishable products.
Method of use and dosage
INDIGO®
Eye drops of 0.05 mg of Naphazoline nitrate and 0.2 mg of Zinc sulfate per ml of solution.
Usually it is advisable to instill, directly into the conjunctival sac, one drop 3-4 times a day, avoiding to exceed the indicated doses.
Warnings INDACO ® Naphazoline and Zinc sulphate
The intake of INDACO® should be preceded by a careful medical examination aimed at clarifying the origin of the complained symptoms and the possible prescribing appropriateness.
Particular caution should be reserved for patients suffering from diabetes, heart disease and hypertension, given the potential systemic side effects of naphazoline, albeit rare.
For the same reason it is recommended not to exceed the recommended doses and times, in order to safeguard the safety of the therapy.
PREGNANCY AND BREASTFEEDING
The aforementioned contraindications to the use of INDACO® also extend to pregnancy and the subsequent period of breastfeeding due to the potential systemic side effects of naphazoline for the health of the fetus and infant.
Interactions
Patients treated with monoamine oxidase inhibitors should not take INDACO® at the same time or earlier than two weeks after discontinuation of treatment due to the increased risk of hypertension.
Contraindications INDACO ® Naphazoline and Zinc sulphate
The use of INDACO® is contraindicated in patients hypersensitive to the active substance or to one of its excipients, in patients with glaucoma or serious eye diseases and in pregnant or breastfeeding women.
Undesirable Effects - Side Effects
The use of INDACO® could cause mydriasis, increased intraocular pressure, nausea and headache.
Fortunately, the potential systemic side effects of therapy are rarer.
Note
INDACO® is a drug not subject to mandatory medical prescription.
The information on INDIGO ® Naphazoline and Zinc Sulphate published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.
